Pipeline - Annexon Biosciences
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	





	






 



		
		  

	
clinical pipeline
for diseases of the body, brain & eye

STOP COMPLEMENT-MEDIATED DISEASES AT THE START

Annexon is pioneering a class of new complement medicines for patients with classical complement-mediated disorders of the body, brain and eye. We are conducting ongoing clinical trials in multiple serious autoimmune, neurodegenerative and ophthalmic diseases.

Advancing Pipeline of ‘Fit for Purpose’ Drug Candidates Across Multiple Complement-Targeted Diseases

Targeting Both Rare & Large Patient Populations

Candidate Design Franchise Indication Preclinical Phase 1 Phase 2 Phase 2/3
ANX005 IV mAb Person icon Guillain-Barré Syndrome (GBS)
Person icon Warm Autoimmune Hemolytic Anemia (wAIHA)
Brain icon Huntington’s Disease (HD)
Brain icon Amyotrophic Lateral Sclerosis (ALS)
ANX007 IVT Fab Eye icon Geographic Atrophy (GA)
ANX009 Subcutaneous Fab Person icon Lupus Nephritis (LN)
ANX105 IV mAb Person iconBrain icon Autoimmune / Neurodegeneration
ANX1502 Oral small molecule Person icon Autoimmune
Thai-chi woman